Concourse Financial Group Securities, Inc. Nuvalent, Inc. Transaction History
Concourse Financial Group Securities, Inc.
- $0
- Q2 2025
Number of Shares
0
Previous 0
NaN%
Holding current value
$0
Previous $0
NaN%
% of portfolio
100.0%
Previous 100.0%
Shares
17 transactions
Others Institutions Holding NUVL
# of Institutions
224Shares Held
61.5MCall Options Held
168KPut Options Held
282K-
Deerfield Management Company, L.P. (Series C) New York, NY18MShares$1.67 Billion31.57% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5.27MShares$490 Million18.77% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.61MShares$428 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$281 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.8MShares$167 Million0.02% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $4B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...